Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

118 results about "Immunotoxin" patented technology

An immunotoxin is an artificial protein consisting of a targeting portion linked to a toxin. When the protein binds to that cell, it is taken in through endocytosis, and the toxin kills the cell. They are used for the treatment of some kinds of cancer and a few viral infections.

Expression of heterologous multi-domain proteins in yeast

This invention demonstrates the utility of a yeast expression system for the expression of functional heterologous multi-domain proteins in yeast. The yeast expression system allows for the inclusion of a plurality of (up to three) modular expression cassettes which may encode multiple polypeptide chains of a heterologous multi-domain protein on a single plasmid (Twin Cassette). Because multiple polypeptide chains may be encoded for by the expression cassettes of the present invention in a single vector, the system can produce equivalent amounts of the multiple polypeptide chains, thereby enhancing the yield of a functional heterologous multi-domain protein. For example, functional monoclonal antibodies (MAbs) comprising a heavy chain and a light chain of an immunoglobulin (IgG), and functional immunotoxins comprising an antibody domain and an oxidase toxin may be produced using the Yeast expression system of the present invention. In addition, functional single chain antibodies, antibody fragments and chimeric antibodies may also be produced.
Owner:APOLIFE

Immunotoxin fusion proteins and means for expression thereof

InactiveUS7696338B2Facilitating proteolytic processingInduce immune toleranceSugar derivativesAntibody mimetics/scaffoldsYeastT cell immunity
The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH OFFICE OF TECH TRANSFER +1

Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof

The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.
Owner:UNITED STATES OF AMERICA +2

Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta)

An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-β expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-β) expressing leukemia cells to specifically destroy these cells. An FR-β monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-β antigen and is produced from a clone resulting from immunization with an FR-β expressing B300-19 cell. The FR-β monoclonal antibody of the present invention specifically reacts with the FR-β antigen of activated macrophages and FR-β expressing leukemia cells and a therapeutic agent of the present invention contains an FR-β antibody immunotoxin which causes apoptosis in activated macrophages and FR-β expressing leukemia cells, as an active ingredient. Further, suitable administration form for the therapeutic agent of the present invention includes intravenous injection as well as joint injection in the case of therapeutic agents for rheumatoid arthritis and juvenile arthritis.
Owner:TAKAMI MATSUYAMA KAGOSHIMA UNIV +1

CD19-specific immunotoxin and treatment method

An immunotoxin for use in, and a method for treating a subject having a cancer associated with malignant B-lineage cells or an autoimmune condition, are disclosed. The immunotoxin includes (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin.
Owner:FRIEDRICH ALEXANDER UNIV ERLANGEN NURNBERG

Immunotoxins directed against malignant cells

The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.
Owner:THE GOVT OF THE U S A AS REPRESENTED BY THE SECT OF THE DEPT OF HEALTH & HUMAN SERVICES +1

T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions

InactiveUS6566082B1Eliminating other undesired immune responsesOptimizationPeptide/protein ingredientsAntipyreticAutoimmune ReactionsAntibody conjugate
The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
Owner:INNOCOMM TECH

Modified proteins, designer toxins, and methods of making thereof

The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and / or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.
Owner:RES DEVMENT FOUND

Recombinant mistletoe lectin (rML)

The invention relates to nucleic acid molecules encoding preproproteins having after maturation the biological activity of the mistletoe lectin dimer, to vectors comprising these nucleic acid molecules, to hosts transformed with said vectors and to polypeptides and / or polypeptide dimers which are encoded by these nucleic acid molecules. The polypeptides and / or polypeptide dimers of the invention are widely therapeutically applicable. Thus, the present invention further relates to immunotoxins as well as to pharmaceutical compositions that contain the polypeptides and / or the polypeptide dimers of the invention. Additionally, the invention relates to diagnostic compositions comprising the nucleic acid molecules of the invention, the polypeptides and / or the polypeptide dimers of the invention and / or primers which hybridize specifically to the nucleic acid molecules of the invention. Finally, the invention relates to plant protective agents comprising the polypeptides of the invention and / or the polypeptide dimers of the invention.
Owner:VISCUM

Ricin inhibitors and methods for use thereof

Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. For a better understanding of the recognition mode between ricin, and adenine-like rings, the interaction energies and geometries were calculated for a number of complexes. Shiga toxin, a compound essentially identical to the protein originally isolated from Shigella dysenteriae, has an active protein chain that is a homologue of the ricin active chain, and catalyzes the same depurination reaction. The present invention is drawn to identifying inhibitors of ricin and Shiga toxin, using methods molecular mechanics and ab initio methods and using the identified inhibitors as antidotes to ricin or Shiga toxin, or to facilitate immunotoxin treatment by controlling non-specific cytotoxicity.
Owner:RES DEVMENT FOUND

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +1

Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens

InactiveUS7754211B2BiocideAntibody ingredientsAntigenC erbb 2 protein
Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.
Owner:RES DEVMENT FOUND

In vitro test system for predicting patient tolerability of therapeutic agents

InactiveUS20060234205A1Simple and efficacious in vitroPredict tolerabilityPeptide/protein ingredientsMicrobiological testing/measurementTolerabilityIn vitro test
Methods for predicting patient tolerability to therapeutic agents, such as cytokines, lymphokines and immunotoxins, are disclosed. The methods utilize an in vitro model of vascular leak syndrome (VLS) to assess the effect of the agent in question on the permeability of large proteins across confluent monolayers of endothelial cells (EC).
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC

Methods for treating cancer using an immuno-toxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer associated protease site cleaved by mmp-2 or mmp-9

InactiveUS20090214543A1HydrolasesAntibody mimetics/scaffoldsPseudomonas exotoxinHuman cancer
The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with a cancer-associated protease site. Also provided are a method of inhibiting or destroying mammalian cancer cells using the immunotoxins of the invention and pharmaceutical compositions for treating human cancer.
Owner:UNIV ZURICH

Recombinant fusion protein and polynucleotide construct for immunotoxin production

InactiveUS20080292646A1Effective internalizingBacteriaAntibody mimetics/scaffoldsNucleotidePseudomonas tolaasii
The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.
Owner:RAMOT AT TEL AVIV UNIV LTD

Methods and means for the treatment of immune-related diseases

The present invention provides novel means and methods for treating unwanted side effects in transplantations, such as GVHD and allograft rejection. The invention provides immunotoxins comprising an antibody and a toxic substance, whereby cocktails of such conjugates are directed to different targets associated with one population of cells, wherein one target is chosen from CD3 or CD7. The preferred combination is a cocktail directed against both CD3 and CD7.
Owner:HENOGEN BV

Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation

The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and administering to the subject pancreatic islet cells from a donor. The immune tolerance inducing treatment regimen, used optionally with adjunct immunosuppressive agents, prevents pancreatic islet cell rejection while maintaining long term islet cell function following xenogeneic and allogeneic pancreatic islet cell transplantation. Thus, the methods of the present invention provide a means for treating diabetes, wherein the need for exogenous insulin or immunosuppressive agents is decreased or eliminated. Also provided is a method of inhibiting a rejection response of a transplant recipient, comprising administering an immunotoxin during the peritransplant period, thereby transiently reducing the number of T-cell lymphocytes and promoting long-term survival of the transplant.
Owner:UNITED STATES OF AMERICA

Immunotoxin derived from a recombinant human autoantibody and method of using thereof

ActiveUS20060013809A1Preventing Myasthenia GravisInduce immune toleranceHybrid immunoglobulinsAntibody ingredientsPseudomonas aeruginosa exotoxin ACDNA library
The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial cDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumour comprising the step of exposing the patient to the immunotoxin of the invention.
Owner:ISIS INNOVATION LTD

Recombinant fusion protein and polynucleotide construct for immunotoxin production

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.
Owner:RAMOT AT TEL AVIV UNIV LTD

Human monoclonal antibodies to dendritic cells

Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Owner:CELLDEX THERAPEUTICS INC

Anti-pd-l1 immunotoxin for use in therapy

The present disclosure relates to a combination of an anti-PD-L1 (Programmed Cell Death 1 Ligand 1) with an ‘immunotoxin’ for use in a method for treating a tumor in a patient. Experimental results are provided for a combination of an anti POL 1 antibody with the radioisotope Indium 111.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins

CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
Owner:UNITED STATES OF AMERICA

Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens

InactiveUS20050163774A1BiocideHybrid immunoglobulinsC erbb 2 proteinAntigen
Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.
Owner:RES DEVMENT FOUND

Compositions and methods for modifying toxic effects of proteinaceous compounds

The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS. Also disclosed are methods for producing peptides that inhibit the induction of VLS by ITs and cytokines. Also disclosed are peptides comprising the (x)D(y) sequence to promote the extravasation of other molecules. Toxins mutated in the (x)D(y) motif or active site residues are disclosed for used in vaccines.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products